New Substituted Isocoumarins and Dihydroisocoumarins and their Cytotoxic Activities

Veronika HAMPL, Isolde WETZEL, Franz BRACHER *, Jürgen KRAUSS

Department of Pharmacy – Center for Drug Research, Ludwig-Maximilians University, Butenandtstr. 5–13, D-81377 Munich, Germany.

* Corresponding author. E-mail: Franz.Bracher@cup.uni-muenchen.de (F. Bracher)

Abstract

New isocoumarins were prepared in an efficient way from 2-iodobenzoic acid derivatives and hept-1-yne in a Sonogashira reaction, followed by spontaneous cyclization. Catalytic hydrogenation gave the corresponding dihydroisocoumarins. A 4-chloroisocoumarin was prepared on an alternative pathway. Some of the new compounds showed moderate cytotoxic activities against a human leukemia cell line (HL 60).

Keywords

Isocoumarins • Dihydroisocoumarins • Sonogashira reaction • Cyclization • Cytotoxicity

Introduction

Isocoumarins are a class of natural lactones with high structural diversity exhibiting a broad spectrum of biological activities [1]. Considerable work has been published over decades about their chemistry [2] and biology [3], and a number of natural and synthetic isocoumarins have been shown to exhibit significant cytotoxic and antitumor activities. Among these are numerous isocoumarins bearing various types of substituents (alkyl, alkenyl or aryl groups) at 3-position, as well as the dihydroisocoumarin AI-77-B (A, Figure 1). The latter one was first isolated from Bacillus pumilus, and shows in vitro cytotoxicity against human malignant A375-S2 and cervical cancer HeLa cells [4]. The paraphaeosphaerins (B) from cultures of Paraphaeosphaeria quadriseptana [5] are biogenetically related to the cytotoxic plant metabolites monocillin I and radicicol. NM-3 (C)
is a synthetic analogue of cytogenin (E), and potentiates antineoplastic effects of other chemotherapeutic agents and inhibits angiogenesis [6]. This compound is in phase I clinical trials. The isocoumarin 185322 (D), an analogue of NM-3, is an inhibitor of microtubule assembly, and induces mitotic arrest and apoptosis of multiple myeloma cells [7]. Ochratoxin A (F), a mycotoxin from Aspergillus ochraceus shows nephrotoxic, hepatotoxic, carcinogenic and teratogenic properties in animals [8]; recently the European Pharmacopoeia introduced a limit test for ochratoxin A in plant material (Method 2.8.22). Scoparine A (G) was isolated from the North African medical plant Pituranthos scoparius [9].

The biological activities of the abovementioned and other isocoumarins and dihydroisocoumarins [10, 11] make this class of compounds interesting leads for development of new anticancer drugs.

In a previous work [12] we prepared a number of isocoumarins and dihydroisocoumarins bearing alkyl and hydroxyalkyl residues at C-3 using a one-pot procedure originally described by Lia and Cheng [13]. Since these products showed only moderate cytotoxic activities, we assumed that additional functional groups at the bicyclic core should be of great importance. An isocoumarin with an isopentyl residue at C-3 was the most cytotoxic one in the previous investigations. This prompted us to investigate the influence of additional lipophilic substituents like halogens (cf. F) and methyl (cf. D) located at various positions of the ring system on the cytotoxicity of 3-alkyl(dihydro)isocoumarins.
Results and Discussion

Chemistry

The isocoumarins 2a–2d were prepared in poor to good yields in one pot reactions starting from commercially available 2-iodobenzoic acid derivatives 1a–d and hept-1-yne involving Sonogashira cross coupling reactions in the presence of zinc chloride [13]. The isocoumarins 2a, 2b [14] and 2d were further hydrogenated under palladium catalysis to give the corresponding dihydroisocoumarins 3a, 3b and 3d (Scheme 1). Hydrogenation of 2c did not appear promising due to the risk of reductive dechlorination.

![Chemical Structures](image)

Sch. 1. a: Triethylamine, ZnCl₂, Pd(PPh₃)₂Cl₂, DMF, 100 °C, 24 h; b: H₂, Pd/C, methanol, 25 °C, 12 h.

The 4-chloroisocoumarin 5 was prepared in a different manner. Methyl 2-iodobenzoate (1e) was reacted in a Sonogashira reaction with hept-1-yne (in the absence of zinc chloride) [15, 16] to give the alkyne 4. Treating 4 with 2 equivalents of CuCl₂ and a catalytic amount of N,N-dicyclohexylammonium chloride [17] resulted in cyclization to the chlorinated isocoumarin 5 (Scheme 2).

![Chemical Structures](image)

Sch. 2. a: Pd(PPh₃)₂Cl₂, Cul, N-ethyl-N,N-dimethylamine, DMF, 25 °C, 12 h; b: CuCl₂, N,N-dicyclohexylammonium chloride, 1,2-dichloroethane, 80 °C, 12 h.
**Biology**

The resulting isocoumarins and dihydroisocoumarins were tested for their cytotoxic activity in a MMT assay using the HL 60 leukemia cell line [18, 19]. The results are shown in Table 1. Since we had found some correlation of the cytotoxic activities with lipophilicity in previous investigations on isocoumarins [12], we also calculated the log P values of the new compounds.

**Tab. 1.** Cytotoxicity of the products against HL 60 cell line and calculated partition coefficients log P (calculated with Chem Draw Ultra 10, Cambridge Soft).

| Compound | IC_{50} [µM] | log P |
|----------|--------------|-------|
| 2a       | ≥100         | 3.32  |
| 2b       | 58           | 3.48  |
| 2c       | ≥100         | 3.88  |
| 2d       | ≥100         | 3.81  |
| 3a       | 49           | 3.89  |
| 3b       | 63           | 3.48  |
| 3d       | 103          | 4.38  |
| 4        | >1000        | 4.28  |
| 5        | ≥100         | 4.74  |
| cisplatin| 5            |       |

**Discussion**

Among the five isocoumarins and three dihydroisocoumarins described here, four compounds, the fluorinated isocoumarin 2b and the dihydroisocoumarins 3a, 3b and 3d, showed measurable, albeit very poor cytotoxic activity. No clear tendency for higher activity of one of the two structural subtypes (2 versus 3) can be deduced from these results. Since the log P values of all tested compounds are in the same range, influences of lipophilicity on cytotoxic activity cannot be deduced as well.

In conclusion, isocoumarins and dihydroisocoumarins containing exclusively lipophilic residues at both rings show significantly decreased cytotoxic activities compared to established analogues (AI-77-B (A): 0.2 to 0.4 µM against A375-S2 and HeLa cells [4], ochratoxin A (F) and stereoisomers thereof: 0.3 to 5 µM against Hep G2 cells [20]) containing additional polar groups (especially hydroxyl groups) at the benzenoid ring.

For obtaining isocoumarins with significant cytotoxicity the presence of polar groups at the ring system seems to be indispensible.

**Experimental**

Elemental analysis: Heraeus CHN Rapid; IR spectra: Perkin-Elmer FT-IR Paragon 1000; MS (EI, 70 eV): Hewlett Packard MS-Engine; HRMS: Jeol Mstation 700; NMR: Jeol GSX 400 (1H: 400 MHz, 13C: 100 MHz); flash column chromatography (FCC): Kieselgel 60 (230–400 mesh, E. Merck, Darmstadt).
**General procedure I: Synthesis of isocoumarins 2a–d**

Pd(PPh₃)₂Cl₂ (0.140 g, 0.20 mmol) and ZnCl₂ (0.496 g, 4.0 mmol) were added under N₂ atmosphere to a solution of aryl iodide (2.0 mmol), hept-1-yne (0.577 g, 6.0 mmol), and triethylamine (10 mmol) in DMF (2 mL). The suspension was heated at 100 °C for 24 h. The components of the suspension were separated by flash column chromatography (n-hexane/ethyl acetate).

**General procedure II: Preparation of dihydroisocoumarins 3a,b,d**

Pd on charcoal (10%) was added to a solution of the isocoumarin in methanol (20 mL). The suspension was stirred for 12 h under H₂ atmosphere at ambient pressure, then the catalyst was filtered off, and the residue was washed with methanol. The combined organic layers were evaporated, and the residue was purified by FCC (n-hexane/ethyl acetate).

### 3-Pentylisochromen-1-one (2a)

Prepared following General procedure I from 0.496 g (2.0 mmol) 2-iodobenzoic acid to give 310 mg (71%) as a pale yellow oil. MS (m/z, %): 216 ([M⁺], 34), 160 (36), 118 (100), IR (KBr), ν (cm⁻¹): 2933, 2857, 1716, 1652, 1459, 1176, 769, 705, 592. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.90 (t, J = 7.5 Hz, 3 H, H-5'), 1.35 (m, 4 H, H-3', H-4'), 1.70 (m, 2 H, H-2'), 2.51 (t, J = 7.5 Hz, 2 H, H-1'), 6.26 (s, 1 H, H-4), 6.74 (dd, J₁ = 8.1 Hz, 1 H, H-5), 7.43 (dd, J₁ = J₂ = 8.1 Hz, 1 H, H-7), 7.66 (dd, J₁ = J₂ = 8.1 Hz, 1 H, H-6). ¹3C NMR (100 MHz, CDCl₃): δ (ppm) 13.92 (C-5'), 22.34 (C-4'), 26.55 (C-2'), 31.13 (C-3'), 33.45 (C-1'), 102.83 (C-4), 120.12 (C-8a), 127.48 (C-7), 129.45 (C-5), 129.46 (C-8), 134.67 (C-6), 137.60 (C-7), 158.28 (C-1). HRMS: Calcd. for C₁₄H₁₆O₂: 216.1150. Found: 216.1100.

### 8-Fluoro-3-pentyl-1H-isochromen-1-one (2b) [14]

Prepared following General procedure I from 0.532 g (2.0 mmol) 6-fluoro-2-iodobenzoic acid to give 39 mg (9%) as a brown oil. MS (m/z, %): 234 ([M⁺], 19), 178 (24), 136 (100), 107 (30), IR (KBr), ν (cm⁻¹): 2956, 2929, 2859, 1731, 1654, 1600, 1562, 1469, 1419, 1378, 1321, 1272, 1240, 1201, 1149, 1087, 1054, 1031, 971, 923, 894, 831, 773, 719, 678, 651, 570, 557. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.91 (t, J = 7.7 Hz, 3 H, H-5'), 1.35 (m, 4 H, H-3', H-4'), 1.70 (m, 2 H, H-2'), 2.50 (t, J = 7.7 Hz, 2 H, H-1'), 6.23 (d, J = 2.3 Hz, 1 H, H-4), 7.12 (m, 2 H, H-5, H-7), 7.61 (m, 1 H, H-6). HRMS: Calcd. for C₁₄H₁₅O₂F: 234.1056. Found: 234.10594. Anal. Calcd. for C₁₄H₁₅O₂F: C, 71.78; H, 6.45. Found: C, 72.27; H, 7.66.

### 6-Chloro-3-pentyl-1H-isochromen-1-one (2c)

Prepared following General procedure I from 0.565 g (2.0 mmol) 4-chloro-2-iodobenzoic acid to give 75 mg (15%) as a brown oil. MS (m/z, %): 252 ([M⁺], 13), 250 ([M⁺], 35), 194 (45), 152 (100), 123 (20), IR (KBr), ν (cm⁻¹): 2956, 2929, 2859, 1774, 1745, 1660, 1614, 1567, 1475, 1376, 1315, 1253, 1157, 1105, 1012, 831, 808, 777, 728, 688, 669. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.91 (t, J = 7.6 Hz, 3 H, H-5'), 1.35 (m, 4 H, H-3', H-4'), 1.70 (m, 2 H, H-2'), 2.52 (t, J = 7.6 Hz, 2 H, H-1'), 6.18 (s, 1 H, H-4), 7.34 (d, J = 2.0 Hz, 1 H, H-5), 7.39 (dd, J₁ = 8.5 Hz, J₂ = 2.0 Hz, 1 H, H-7), 8.17 (d, J = 8.5 Hz, 1 H, H-8). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 13.94 (C-5'), 22.35 (C-4'), 26.50 (C-2'), 31.14 (C-3'), 33.55 (C-1'), 102.02 (C-4), 118.41 (C-8a), 124.56 (C-5), 128.02 (C-7), 131.20 (C-8), 139.00 (C-4a), 158.28 (C-1)
141.34 (C-6), 159.86 (C-3), 162.30 (C-1). HRMS: Calcd. for C_{14}H_{15}O_{2}Cl: 250.0761. Found: 250.0834. Anal. Calcd. for C_{14}H_{15}O_{2}Cl: C, 67.07; H, 6.03. Found: C: 67.93; H: 6.90.

5-Methyl-3-pentyl-1H-isochromen-1-one (2d)

Prepared following General procedure I from 0.524 g (2.0 mmol) 2-iodo-3-methylbenzoic acid to give 80 mg (18 %) as a yellow oil. MS (m/z, %): 230 ([M]+·, 48), 174 (37), 132 (100), 103 (13). IR (KBr), ν (cm⁻¹): 2927, 2857, 1724, 1652, 1465, 1380, 1270, 1174, 1058, 1022, 759, 705, 584. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.81 (t, J = 7.6 Hz, 3 H, H-5'), 1.29 (m, 4 H, H-3', H-4'), 1.65 (m, 2 H, H-2'), 2.39 (s, 3 H, Ar-CH₃), 2.47 (t, J = 7.6 Hz, 3 H, H-1'), 6.29 (s, 1 H, H-4), 7.26 (dd, J₁ = J₂ = 7.8 Hz, 1 H, H-7), 7.44 (d, J = 7.8 Hz, 1 H, H-6), 8.05 (d, J = 7.8 Hz, 1 H, H-8). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 13.96 (C-5'), 18.72 (Ar-CH₃), 22.45 (C-4'), 26.78 (C-2'), 31.21 (C-3'), 33.86 (C-1'), 99.66 (C-4), 120.12 (C-4a), 127.00 (C-7), 127.36 (C-8), 135.90 (C-8a), 136.32 (C-5), 157.89 (C-3), 163.52 (C-1). HRMS: Calcd. for C_{14}H_{18}O_{2}: 230.1307. Found: 230.1317. Anal. Calcd. for C_{14}H_{18}O_{2}: C, 77.38; H, 9.74. Found: C, 77.17; H, 8.03.

(±)-3-Pentylisochroman-1-one
(rac-(3R)-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3a)

Following General procedure II from 200 mg (0.925 mmol) 3-pentylisochromen-1-one (2a) using 20 mg Pd on charcoal (10 %) to give 160 mg (80 %) as a colourless oil. MS (m/z, %): 218 ([M]+·, 12), 147 (72), 118 (100), 105 (28). IR (KBr), ν (cm⁻¹): 2943, 2855, 1705, 1650, 1455, 1170, 765, 701, 593. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.91 (t, J = 7.2 Hz, 3 H, H-5'), 1.34 (m, 4 H, H-3', H-4'), 1.47 (m, 1 H, H-2'), 1.58 (m, 1 H, H-2'), 1.72 (m, 1 H, H-1'), 1.88 (m, 1 H, H-1'), 2.94 (m, 2 H, H-4), 4.52 (m, 1 H, H-3), 7.24 (dd, J₁ = J₂ = 7.6 Hz, 1 H, H-5), 7.38 (dd, J₁ = J₂ = 7.6 Hz, 1 H, H-6), 7.50 (m, 1 H, H-6). ¹³C NMR (125 MHz, CDCl₃) δ (ppm): 14.01 (C-5'), 22.53 (C-4'), 24.55 (C-2'), 31.58 (C-4), 33.65 (d, J = 2.4 Hz, C-8a), 34.94 (C-1'), 77.39 (C-3), 125.23 (C-4a), 127.37 (C-5), 127.58 (C-6), 130.23 (C-8), 133.64 (C-7) 139.25 (C-8a), 161.43 (C-1), 162.99 (C-4a). HRMS: Calcd. for C_{15}H_{18}O_{2}: 218.1286. Found: 218.1286. Anal. Calcd. for C_{15}H_{18}O_{2}: C, 77.38; H, 9.74. Found: C, 77.17; H, 8.03.

(±)-8-Fluoro-3-pentylisochroman-1-one
(rac-(3R)-8-fluoro-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3b)

Following General procedure II from 28 mg (0.12 mmol) 8-fluoro-3-pentylisochromen-1-one (2b) using 5 mg Pd on charcoal (10 %) to give 25 mg (89 %) as a pale yellow oil. IR (KBr), ν (cm⁻¹): 3456, 2955, 2928, 2858, 1731, 1660, 1615, 1582, 1470, 1378, 1358, 1253, 1099, 1057, 1031, 803, 780, 727, 690. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.91 (t, J = 7.1 Hz, 3 H, H-5'), 1.33 (m, 4 H, H-3', H-4'), 1.45 (m, 1 H, H-2'), 1.57 (m, 1 H, H-2'), 1.71 (m, 1 H, H-1'), 1.87 (m, 1 H, H-1'), 2.94 (m, 2 H, H-4), 4.48 (m, 1 H, H-3), 7.09 (m, 2 H, H-5 and H-7), 7.50 (m, 1 H, H-6). ¹³C NMR (125 MHz, CDCl₃) δ (ppm): 12.83 (C-5'), 113.87 (d, J = 6.9 Hz, C-8a), 116.01 (d, J = 21.6 Hz, C-7), 123.07 (d, J = 3.8 Hz, C-5), 134.95 (d, J = 10.0 Hz, C-6), 141.90 (C-4a), 161.43 (C-1), 162.99 (d, J = 264.8 Hz, C-8). HRMS: Calcd. for C_{15}H_{20}O_{2}: 236.1213. Found: 236.1195.
(±)-5-Methyl-3-pentyl-isochroman-1-one
(rac-(3R)-5-methyl-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3d)

Following General procedure II from 40 mg (0.17 mmol) 5-methyl-3-pentylisochromen-1-one (2d) using 4 mg Pd on charcoal (10 %) to give 35 mg (89 %) as a colourless oil. MS (m/z, %): 232 ([M]+, 21), 161 (63), 133 (100), 105 (29). IR (KBr), ν (cm⁻¹): 2956, 2929, 2859, 1774, 1745, 1660, 1567, 1475, 1376, 1315, 1253, 1157, 1105, 1012, 831, 808, 777, 728, 688, 669. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.91 (t, J = 7.0 Hz, 3 H, H-5'), 1.34 (m, 4 H, H-3', H-4'), 1.49 (m, 1 H, H-2'), 1.59 (m, 1 H, H-2'), 1.74 (m, 1 H, H-1'), 1.89 (m, 1 H, H-1'), 2.32 (s, 3 H, Ar-CH₃), 2.77 (dd, J₁ = 3.3 Hz, J₂ = 16.6 Hz, 1 H, H-4), 2.92 (dd, J₁ = 3.3 Hz, J₂ = 16.6 Hz, 1 H, H-4), 4.48 (m, 1 H, H-3), 7.27 (dd, J₁ = J₂ = 7.7 Hz, 1 H, H-7), 7.39 (d, J = 7.7 Hz, 1 H, H-6), 7.96 (d, J = 7.7 Hz, 1 H, H-8). ¹³C NMR (125 MHz, CDCl₃): δ (ppm) 13.98 (C-5'), 18.85 (Ar-CH₃), 22.49 (C-4'), 24.62 (C-2'), 31.57 (C-3'), 35.08 (C-1'), 77.25 (C-3), 125.20 (C-4a), 126.93 (C-7), 128.07 (C-8), 134.94 (C-6), 135.00 (C-8a), 137.78 (C-5), 166.08 (C-1). HRMS: Calcd. for C₁₅H₂₀O₂: 232.14633. Found: 232.14310.

Methyl 2-(hept-1-yn-1-yl)benzoate (4)

2.62 g (10.0 mmol) methyl 2-iodobenzoate, 0.96 g (10.0 mmol) hept-1-yne, 200 mg (2.4 mmol) CuI and 400 mg (0.6 mmol) PdCl₂(PPh₃)₂ were dissolved in 20 mL N-ethyl-N,N,N-dimethylamine and the solution was stirred for 12 h at room temperature. The solvent was evaporated and the residue was quenched with 20 mL 5% aqueous Na₂SO₃-solution. The mixture was extracted with diethyl ether (3 x 25 mL) and the combined organic layers were dried over Na₂SO₄. The solvent was evaporated and the residue was purified by FCC (isohexane/ethyl acetate 5:1) to give 740 mg (32 %) of 4 as a pale brown oil. MS (m/z, %): 230 ([M]+, 22), 215 (36), 174 (100), 159 (72), 133 (96), 115 (42). IR (KBr), ν (cm⁻¹): 3066, 2954, 2931, 2859, 2235, 1733, 1565, 1484, 1446, 1342, 1294, 1274, 1249, 1130, 1083, 981, 881, 757, 701, 538. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.90 (t, J = 7.2 Hz, 3 H, H-7'), 1.35 (m, 2 H, H-5'), 1.43 (m, 2 H, H-6'), 1.62 (m, 2 H, H-4'), 2.44 (t, J = 7.2 Hz, 2 H, H-3'), 3.88 (s, 3 H, OCH₃), 7.27 (ddd, J₁ = J₂ = 7.8 Hz, J₃ = 1.2 Hz, 1 H, H-4), 7.38 (ddd, J₁ = J₂ = 7.8 Hz, J₃ = 1.2 Hz, 1 H, H-5), 7.48 (dd, J₁ = J₂ = 1.2 Hz, 1 H, H-3), 7.85 (dd, J₁ = J₂ = 1.2 Hz, 1 H, H-6). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 13.91 (C-7'), 19.66 (C-6'), 22.16 (C-4'), 28.31 (C-5'), 31.03 (C-3'), 51.93 (OCH₃), 79.10 (C-1'), 95.95 (C-2'), 124.50 (C-2), 127.00 (C-4), 130.03 (C-5), 131.36 (C-3), 131.38 (C-1), 134.10 (C-6), 166.91 (C=O). Anal. Calcd. for C₁₅H₁₈O₂: C, 78.26; H, 7.83. Found: C, 78.69; H, 7.76.

4-Chloro-3-pentyl-1H-isochromen-1-one (5)

0.690 g (3.20 mmol) methyl 2-(hept-1-ynyl)-benzoate (4), 0.081 g (6.2 mmol) CuCl₂, 0.065 g (0.30 mmol) N,N-dicyclohexylammonium chloride and 30 mL 1,2-dichloroethane were dissolved under N₂ atmosphere and heated at 80 °C with stirring. After 12 h the solvent was evaporated and the residue was purified by FCC (isohexane/ethyl acetate 10:1) to give 580 mg (32 %) of 5 as a pale brown oil. MS (m/z, %): 252 ([M]+, 31), 250 ([M]+, 100), 215 (18), 194 (69), 165 (26), 159 (51), 152 (43). IR (KBr), ν (cm⁻¹): 3072, 3035, 2956, 2931, 2859, 1745, 1631, 1602, 1567, 1479, 1465, 1319, 1288, 1052, 1031, 975, 964, 925. ¹H NMR (400 MHz, CDCl₃): δ (ppm) 0.90 (t, J = 7.7 Hz, 3 H, H-5'), 1.37 (m, 4 H, H-3', H-4'), 1.73 (m, 2 H, H-2'), 2.75 (t, J = 7.7 Hz, 2 H, H-1'), 7.53 (ddd, J₁ = J₂ = 7.8 Hz, J₃ = 1.2 Hz, 1 H, H-7), 7.79 (m, 2 H, H-5, H-6), 8.26 (d, J = 7.8 Hz, 1 H, H-8). ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 13.89 (C-5'), 22.30 (C-4'), 26.41 (C-2'), 31.17 (C-1', 3'), 110.89 (C-4), 112.90 (C-6), 124.07 (C-2), 127.40 (C-4), 130.05 (C-5), 131.37 (C-3), 131.39 (C-1), 134.10 (C-6), 166.91 (C=O). Anal. Calcd. for C₁₅H₁₂ClO₂: C, 76.88; H, 6.40. Found: C, 76.98; H, 6.39.
120.13 (C-8a), 123.14 (C-5), 128.35 (C-7), 129.73 (C-8), 135.17 (C-6), 135.54 (C-4a), 154.66 (C-3), 161.31 (C-1). Anal. Calcd. for C_{14}H_{15}O_{2}Cl: C, 67.07; H, 6.03. Found: C, 67.24; H, 6.45.

**MTT assay**

A solution of the substance in dimethyl sulfoxide (1 μl, concentrations in the range from $10^{-9}$ to $10^{-4}$ mol/l) was incubated with 99 μl of a suspension of HL 60 cells (9 × 10^5 cells/ml) in RPMI 1640 medium (PAA Laboratories) with 10% FKS in 96 well plates for 24 h. Then, 10 μl of a solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in PBS (5 mg/ml) were added and the plate was incubated for another 2 h. The cells were quenched with 190 μl dimethyl sulfoxide and after a few min, the plates were evaluated on a Dynatech MRX at a wavelength of 570 nm; the reference wavelength was 630 nm [18]. The experiments were performed in triplicate.

**Acknowledgement**

We thank Martina Stadler for technical support.

**Authors Statement**

**Competing Interests**

The authors declare no conflict of interest.

**References**

[1] Hill RA.
Naturally occurring isocoumarines.
In: Progress in the Chemistry of Organic Natural Products, Vol. 49.
Wien, New York: Springer Verlag, 1986: 1–78.

[2] Napolitano E.
The synthesis of isocoumarins over the last decade. A review.
Org Prep Proced Int. 1997; 29: 631–664.
doi:10.1080/00304949709355245

[3] Markaryan EA, Samodurova AG.
Advances in the chemistry of isochroman.
Russ Chem Rev. 1989; 58: 479–493.
doi:10.1070/RC1989v058n05ABEH003455

[4] Huang Y-F; Li L-H, Tian L, Qiao L, Hua H-M, Pei YH.
Sg17-1-4, a novel isocoumarin from a marine fungus Alternaria tenuis Sg17-1.
J Antibiot. 2006; 59: 355–357.
doi:10.1038/ja.2006.50

[5] Wijerantne EMK, Paranagama PA, Gunatilaka AAL.
Five new isocoumarins from Sonoran desert plant-associated fungal strains Paraphaeosphaeria quadriseptata and Chaetomium chiversii.
Tetrahedron. 2006; 62: 8439–8446.
doi:10.1016/j.tet.2006.06.089
[6] Reimer CL, Agata N, Tamman JG, Bamberger M, Dickerson WM, Kamphaus GD, Rook SL, Milhollen M, Fram R, Kalluri R, Kufe D, Kharbanda S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res. 2002; 62: 789–795. PMID:11830534

[7] Kawano T, Agata N, Kharbanda S, Avigan D, Kufe D. A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. Cancer Chemother Pharmacol. 2007; 59: 329–335. doi:10.1007/s00280-006-0274-x

[8] Van der Merwe KJ, Steyn PS, Fourie L, Scott DB, Theron JJ. Ochratoxin A, a toxic metabolite produced by Aspergillus ochraceus Wilh. Nature. 1965, 205: 1112–1113. doi:10.1038/2051112a0

[9] Hamada H, Mohammed B, Massiot G, Long C, Lavaud C. Alkylated isocoumarins from Pituranthos scoparius. Nat Prod Res. 2004, 18: 409–413. doi:10.1080/14786410310001639259

[10] Zhang W, Krohn K, Draeger S, Schulz B. Bioactive isocoumarins isolated from the endophytic fungus Microdochium bolleyi. J Nat Prod. 2008; 71: 1078–1081. doi:10.1021/np800095g

[11] Azumi M, Ogawa K-I, Fujita T, Takeshita M, Yoshida R, Furumai T, Igarashi Y. Bioactive microbial metabolites. Part 33. Bacilosarcsins A and B, novel bioactive isocoumarins with unusual heterocyclic cores from the marine-derived bacterium Bacillus subtilis. Tetrahedron. 2008; 64: 6420–6425. doi:10.1016/j.tet.2008.04.076

[12] Wetzel I, Bracher F, Krauß J. Short approach towards new isocoumarins and dihydroisocoumarins and investigation of their cytotoxic activities. Z Naturforsch B. 2009; 64b: 313–318.

[13] Liao H-Y, Cheng C-H. Synthesis of isocoumarins from o-iodobenzoic acid and terminal acetylenes mediated by palladium complexes and zinc chloride. J Org Chem. 1995; 60: 3711–3716. doi:10.1021/jo00117a023

[14] Compound 2b has been obtained earlier via tandem Stille coupling with an allenylstannane: Cherry K, Parra J-L, Thibonnet J, Duchene A, Abarbri M. Synthesis of isocoumarins and α-pyrones via tandem Stille reaction/heterocyclization. J Org Chem. 2005; 70: 6669–6675. doi:10.1021/jo050638z

[15] Rudyanto M, Kobayashi K, Honda T. Synthetic studies on natural isocoumarins and isocarbostyril derivatives having an alkyl substituents at the 3-position: Total synthesis of scoparines A and B (VIII), and ruprechstyril (V). Heterocycles. 2009; 79: 753–764. doi:10.3987/com-08-s(d)40

[16] Krauß J, Unterreitmeier D, Neudert C, Bracher F. Short and efficient approach towards macrocyclic lactones based on Sonogashira reaction. Arch Pharm Pharm Med Chem. 2005; 338: 605–608. doi:10.1002/ardp.200500132
[17] Liang Y, Xie Y-X, Li J-H. Cy2NH×HX-promoted cyclizations of o-(alk-1-ynyl)benzoates and (Z)-alk-2-en-4-ynoate with copper halides to synthesize isocoumarins and α-pyrone. Synthesis. 2007; 400–406.
doi:10.1002/ardp.200500132

[18] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55–63.
doi:10.1016/0022-1759(83)90303-4

[19] Collins S, Gallo R, Gallagher R. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977; 270: 347–349.
doi:10.1038/270347a0

[20] Cramer B, Harrer H, Nakamura K, Uemura D, Humpf HU. Total synthesis and cytotoxicity evaluation of all ochratoxin A stereoisomers. Bioorg Med Chem. 2010; 18: 343–347.
doi:10.1016/j.bmc.2009.10.050